Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (131-140 of 279) with videos related to

Pageof 28
Sort By:
Haematologica|February 18, 2017
Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocolsMarius Rohde, Bettina R Bonn, Martin Zimmermann, et al.
Leukemia|February 27, 2024
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control studyStefanie V Junk, Alisa Förster, Gunnar Schmidt, et al.
Leukemia|July 5, 2022
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemiaPaula Möker, Udo Zur Stadt, Martin Zimmermann, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
British Journal of Haematology|September 20, 2011
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective surveyKlaus Bienemann, Birgit Burkhardt, Simon Modlich, et al.
Haematologica|April 18, 2020
Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study groupOlga Moser, Martin Zimmermann, Ulrike Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse TrialFabian Knörr, Laurence Brugières, Marta Pillon, et al.
Leukemia|March 24, 2020
Leukemia-induced dysfunctional TIM-3<sup>+</sup>CD4<sup>+</sup> bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patientsFranziska Blaeschke, Semjon Willier, Dana Stenger, et al.
Haematologica|August 5, 2021
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study GroupGabriele Escherich, Udo Zur Stadt, Arndt Borkhardt, et al.
Blood|April 10, 2010
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocolGunnar Cario, Martin Zimmermann, Renja Romey, et al.
Pageof 28

Showing results (131-140 of 279) with videos related to

Sort By:
Pageof 28
Haematologica|February 18, 2017
Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocolsMarius Rohde, Bettina R Bonn, Martin Zimmermann, et al.
Leukemia|February 27, 2024
Germline variants in patients developing second malignant neoplasms after therapy for pediatric acute lymphoblastic leukemia-a case-control studyStefanie V Junk, Alisa Förster, Gunnar Schmidt, et al.
Leukemia|July 5, 2022
Characterization of IG-MYC-breakpoints and their application for quantitative minimal disease monitoring in high-risk pediatric Burkitt-lymphoma and -leukemiaPaula Möker, Udo Zur Stadt, Martin Zimmermann, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing DataGudrun Würthwein, Claudia Lanvers-Kaminsky, Christian Siebel, et al.
British Journal of Haematology|September 20, 2011
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective surveyKlaus Bienemann, Birgit Burkhardt, Simon Modlich, et al.
Haematologica|April 18, 2020
Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study groupOlga Moser, Martin Zimmermann, Ulrike Meyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse TrialFabian Knörr, Laurence Brugières, Marta Pillon, et al.
Leukemia|March 24, 2020
Leukemia-induced dysfunctional TIM-3<sup>+</sup>CD4<sup>+</sup> bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patientsFranziska Blaeschke, Semjon Willier, Dana Stenger, et al.
Haematologica|August 5, 2021
Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study GroupGabriele Escherich, Udo Zur Stadt, Arndt Borkhardt, et al.
Blood|April 10, 2010
Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocolGunnar Cario, Martin Zimmermann, Renja Romey, et al.
Pageof 28